running-list-of-examples-of-covid-19-vaccine-inefficacy

Running List of Examples of COVID-19 ‘Vaccine’ Inefficacy


Here is a running list of anecdotal examples and general scientific data that shows the COVID-19 “vaccines” and boosters are not effective at slowing the spread of the disease. And, for the most part, not effective at mitigating severe disease and death either.






https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1032859/Vaccine_surveillance_report_-_week_45.pdf?fbclid=IwAR3ovS_LZuk6hh0wF2MWP08HGPOekcKCfDp4q5EVzeEAXVS_J0spMEHSMo4


LINK TO QUOTE ON WHO’S SITE


LINK TO TWEET FROM BARSTOOL PACK


“Indeed, the original Pfizer trial demonstrated a statistically significant 40% increase in ‘suspected COVID’, with 409 cases in the vaccination arm in the first week of the trial, compared with 287 in the placebo arm.”Clare Craig, Diagnostic Pathologist, in a letter to The British Medical Journal.

LINK TO PFIZER REVIEW MEMORANDUM

LINK TO DANISH STUDY SHOWING 40% INCREASE IN INFECTION RATE POST VACCINATION.


LINK TO MASSACHUSETTS DEPARTMENT OF PUBLIC HEALTH SOURCE



LINK TO TWEET


LINK TO TWEET / SOURCED FROM: OUR WORLD IN DATA


LINK TO TWEET / SOURCED FROM: OUR WORLD IN DATA


LINK TO TWEET


LINK TO POST IN THE TIMES OF ISRAEL


Journal: Unpublished, medical archive

TITLE: Correlation of SARS-CoV-2 Breakthrough Infections to Time-from-vaccine;
Preliminary Study

METHODS:

Data regarding the duration of protection are essential for effective resource allocation and
vaccine administration, such as the need and urgency of a third dose.15,16 Israel’s rapid rollout
of the mass vaccination campaign allows us to investigate the correlation between time-from vaccine and vaccine effectiveness against the Delta variant.


To this end, we conducted a retrospective cohort study comparing the incidence rates of
breakthrough infections between early and late vaccinees, using data from Maccabi
Healthcare Services (MHS),
 Israel’s second largest Health Maintenance Organization, which
covers 2.5 million members (25% of the population) and provides a representative sample of
the Israeli population.

CONCLUSION:

In this cohort of MHS members, all of whom are vaccinated with the BioNTech/Pfizer
mRNA BNT162b2 vaccine in a two-dose regimen, we identified a significant correlation between time-from-vaccine and afforded protection against SARS-CoV-2 infection
. The risk for breakthrough infection was significantly higher for early vaccinees compared to those vaccinated later

Taken together, the study suggests a possible relative decrease in the long-term protection of
the BNT162b2 vaccine against the Delta variant of SARS-CoV-2
. This preliminary finding
should be evaluated in future studies, including a comparison to long-term protection against
different strains, and prospective clinical trials to examine the effect of a booster vaccine
against breakthrough infection.

LINK TO STUDY


LINK TO CDC PAGE FOR BARNSTABLE, MASSACHUSETTS OUTBREAK AMONGST VACCINATED PEOPLE.


LINK TO STUDY IN THE JOURNAL VACCINES


LINK TO STUDY IN INFECTIOUS DISEASES


LINK TO STUDY IN CLINICAL MICROBIOLOGY AND INFECTION


LINK TO STUDY ON THE CDC WEBSITE


LINK TO STUDY IN THE JOURNAL OF TRAVEL MEDICINE


LINK TO STUDY IN MMWR


LINK TO ARTICLE IN NATURE MEDICINE


LINK TO THE STUDY IN THE BRITISH MEDICAL JOURNAL


Link to the study from the U.S. Government’s Covid Response Team at the Centers for Disease Control and Prevention (CDC)


LINK TO TWEET / LINK TO ARTICLE IN NEWSWEEK


LINK TO TWEET / SOURCE: OUR WORLD IN DATA


LINK TO TWEET / SOURCE: OUR WORLD IN DATA


LINK TO TWEET / LINK TO ARTICLE IN THE NEW YORK POST


LINK TO ARTICLE IN THE WALL STREET JOURNAL


LINK TO TWEET


LINK TO TWEET / LINK TO ARTICLE ON PATCH.COM


LINK TO TWEET / LINK TO ARTICLE IN THE VERMONT DAILY CHRONICLE


LINK TO TWEET / LINK TO ARTICLE IN THE HILL


LINK TO TWEET / LINK TO ARTICLE IN INSIDER PAPER


LINK TO TWEET


LINK TO TWEET


LINK TO CORRESPONDENCE IN THE LANCET


LINK TO CDC REPORT


LINK TO TWEET / LINK TO AP STORY


LINK TO TWEET / LINK TO PREPRINT IN THE LANCET




LINK TO TWEET / LINK TO ARTICLE IN THE WASHINGTON POST


LINK TO TWEET / LINK TO DATA SOURCE


https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1037987/Vaccine-surveillance-report-week-48.pdf


LINK TO TWEET / LINK TO ARTICLE IN DER TAGESSPIEGEL


LINK TO TWEET / LINK TO TWEET 2 / LINK TO ARTICLE IN NPR



Journal: Vaccine

TITLE: COVID-19 vaccine – Long term immune decline and breakthrough infections

METHODS: “We conducted a 5-month longitudinal prospective study involving vaccinated healthcare personnel, who were tested monthly for antibody titer, and sampled biweekly and on clinical indication for SARS-COV-2 polymerase chain reaction (PCR), to determine antibody decline and breakthrough infection.”

CONCLUSION: “100 participants were recruited to the study. Antibody titer reached the climate after one month of the second dose of the vaccine, and declined rapidly thereafter: the median antibody levels were 895; 22,266; 9,682; 2,554 and 1,401 AU/ml in the day of the second dose, and in one month interval thereafter, respectively. In other words, four months after vaccination, the mean antibody level was 6% of the peak levels. During the study period, 4 breakthrough infections were diagnosed, 2 of which were asymptomatic, and the remaining two were mild cases; sharp elevation of antibody titer was seen after infection.

Antibody titer drops rapidly one month after the second dose of the vaccine. All infections within the study period were mild or asymptomatic, after which titer elevations were seen.”

LINK TO STUDY


Journal: Nature Communications [Published November 4, 2021]

TITLE: Correlation of SARS-CoV-2-breakthrough infections to time-from-vaccine

METHODS: “The study population consisted of all MHS members aged 16 and above who received the second dose of the vaccine between January and April 2021. Individuals were considered fully vaccinated if they received two doses of the BNT162b2, the second one administered within the 21-to-28-day interval set by national guidelines. The minority who did not follow the guidelines included those infected after the first dose or those suffering an intercurrent illness that delayed the administration of the second dose.”

CONCLUSION: In this cohort of MHS members, all of whom are vaccinated with the BioNTech/Pfizer mRNA BNT162b2 vaccine in a two-dose regimen, we identified a significant correlation between time-from-vaccine and afforded protection against SARS-CoV-2 infection. The risk for breakthrough infection was significantly higher for Early Vaccinees compared with those vaccinated later with an additional trend for higher risk for hospitalization among the Early Vaccinees group. Our results correspond to recent publications that demonstrate a significant decline in antibody levels and immune systems compounds over time following the second dose of vaccination.”

LINK TO STUDY


LINK TO TWEET / LINK TO TWEET 2 / LINK TO ARTICLE IN THE EPOCH TIMES


LINK TO TWEET


LINK TO TWEET








LINK TO TWEET / LINK TO ARTICLE IN THE HERALD

Feature image: Jernej Furman

(Visited 3 times, 1 visits today)

Accessibility Toolbar